Spectrophotometric determination of tranexamic acid using vanillin

12 downloads 0 Views 106KB Size Report
药学学报 Acta Pharmaceutica Sinica 2009, 44 (2): 175−180. · 175 ·. Spectrophotometric determination of tranexamic acid using vanillin. F.M.A. Rind. 1*.
药学学报 Acta Pharmaceutica Sinica 2009, 44 (2): 175−180

·

175 ·

Spectrophotometric determination of tranexamic acid using vanillin F.M.A. Rind1*, M.G.H. Laghari1, A.H. Memon1, U.R. Mughal1, F. Almani1, N. Memon1, M.Y. Khuhawar2, M.L. Maheshwari1 (1. Faculty of Pharmacy, University of Sindh, Jamshoro, Pakistan; 2. Institute of Chemistry, Faculty of Natural Sciences, University of Sindh, Jamshoro, Pakistan)

Abstract: A new spectrophotometric method has been examined for the determination of the tranexamic acid (TA) by derivatization with vanillin (VAN). The molar absorptivity of TA was calculated 25 160 L·mol−1·cm−1 at λmax 354 nm and obeyed the Beer’s law within 0.5−2.5 µg·mL−1. The color reaction was highly stable and did not show any change in absorbance up to 24 h. The method was applied for the analysis of TA from capsules, injections and tooth pastes. The amounts of TA found in capsules, injections and tooth pastes of various pharmaceutical companies were observed with 249.0−250.9 mg/capsule, 249.3−250.7 mg/injection and 0.048%−0.049% in tooth pastes with relative standard deviation (RSD) 0.2%−5.0% (n = 3). Key words: tranexamic acid; vanillin; spectrophotometry CLC number: R917

Document code: A

Article ID: 0513-4870 (2009) 02-0175-06

Introduction

Materials and methods

Tranexamic acid (TA) is a hydrophilic drug used as an anti-fibrinolytic agent[1, 2] to reduce bleeding after cardiac surgery[3] and arthroplastic surgery[4]. It also exhibits anti-inflammatory[5], whitening effects on skin[6].

Materials and reagents All the chemicals and reagents used were of analytical or pharmaceutical grades. The double distilled water used throughout the study was obtained from distillation plant all made of glass. Pure tranexamic acid (TA), vanillin (VAN) and acetic acid were obtained from E. Merck (Germany), ethanol from BDH (UK) and sodium acetate from Fluka

The prophylactic administration of TA 10 mg·kg−1·h−1 significantly reduced red blood cell transfusion in liver transplantation[7]. Several analytical methods have been reported for the analysis of TA, based on spectrophotometric[8−15], flourimetric[16], thin layer chromatographic[17], ion exchange chromatographic[18], high performance liquid chromatographic[19−26] and gas chromatographic[27, 28] techniques. For spectrophotometric analysis, the determination is carried out using suitable reagents such as 2, 4, 6-trinitrobenzosulfonic acid, p-dimethylaminobenzaldehyde, naphthalene-2,3dicarboxaldehyde, 2-hydroxynaphthaldehyde[10, 11, 14, 20]. The derivatization either increases the molar absorptivity or produces bathochromic shift in the absorbance. Therefore, vanillin (VAN) is examined for the first time as a derivatizing reagent for spectrophotometric determination of TA in various pharmaceutical preparations. Received: 2008-10-08. * Corresponding author Tel: +9222772486, E-mail: [email protected]

(Switzerland). Buffer solutions between pH 1−10 at unit internal were prepared from hydrochloric acid (1 mol·L−1), potassium chloride (1 mol·L−1 ) (pH 1−2), acetic acid (1 mol·L−1), sodium acetate (1 mol·L−1) (pH 3−6), ammonium acetate (1 mol·L−1) (pH 7), sodium bicarbonate (1 mol·L−1), sodium carbonate (saturated solution) (pH 8−9) and ammonium chloride (1 mol·L−1) and ammonia solution (1 mol·L−1) (pH 10−11). The solution of VAN 1% (w/v) was prepared in distilled water (100 mL). The solution of TA (10 μg·mL−1) was prepared by dissolving 0.001 g TA in double distilled water (100 mL). The spectrophotometric studies were carried out with a double beam spectrophotometer UV-1601 (Shimadzu Corporation, Japan) with dual silica 1cm cuvettes. Analytical procedure The aqueous solution (0.5−2.5 mL) containing TA (5−25 µg) was transferred

·

176 ·

药学学报 Acta Pharmaceutica Sinica 2009, 44 (2): 175−180

to 10 mL calibrated stoppered volumetric flasks and were added 3 mL VAN in double distilled water 1% (w/v), followed by HCl-KCl buffer pH 1 (1 mL). The contents were heated on water bath at (90±5) ℃ for 15 min. The solutions were cooled at room temperature and the volumes were adjusted to mark with ethanol. The absorbance was measured at λmax 354 nm against reagent blank which was prepared in a similar way by omitting the addition of TA. UV method un-derivatized The aqueous solution (0.5−2.5 mL) containing TA (500−2 500 µg) was transferred to 10 mL calibrated stoppered volumetric flasks and the volumes were adjusted to mark with ethanol. The absorbance was measured at λmax 207 nm against ethanol. The molar absorptivity was observed 739 L·mol −1·cm−1. Analysis of TA from capsules dosage form For the analysis of TA contents from capsules, thirteen samples of different pharmaceutical companies were collected. The sample (0.25 g) from well ground mixture of at least five capsules of each of the following sample: Aneptil (Alina Combine (Pvt) Ltd. Karachi, Pakistan), Btrol (Bosch Pharmaceuticals (Pvt) Ltd. Karachi, Pakistan), Haematrix (Macter International (Pvt) Ltd. Karachi, Pakistan), Maxna (Ali Gohar Pharmaceuticals (Pvt) Ltd. Karachi, Pakistan), Ranmic (Medicraft Pharmaceutical (Pvt) Ltd. Lahore, Pakistan), Transamin (Hilton Pharma (Pvt) Ltd. Karachi, Pakistan), Transcam (Chas A.Mendoza Karachi, Pakistan), Tranxic (Lisko Pakistan (Pvt) Ltd. Karachi, Pakistan), Traumax (Siza International (Pvt) Ltd. Lahore, Pakistan), Traxyl (Organon Pakistan (Pvt) Ltd. Karachi, Pakistan), Xamig (Highnoon Laboratories, (Pvt) Ltd. Lahore, Pakistan), Xed (Indus Pharma (Pvt) Ltd. Karachi, Pakistan), Zatranex (Zafa Pharmaceutical Laboratories (Pvt) Ltd. Karachi, Pakistan) was dissolved in 100 mL of double distilled water. The solution 0.1 mL was further diluted up to 25 mL with double distilled water. The solution (1 mL) was transferred to volumetric flask (10 mL) and the procedure described in “Analytical procedure” was followed. Analysis of TA from injections dosage form For the analysis of TA contents from ten injections of different pharmaceutical companies, the sample (5 mL) from each of the TA injection: B-STOP (Saydon Pharmaceuticals Industry (Pvt) Ltd. Peshawar, Pakistan), Haematrix (Macter International (Pvt) Ltd.

Karachi, Pakistan), Maxna (Ali Gohar Pharmaceuticals (Pvt) Ltd. Karachi, Pakistan), Tranamin (Akson Pharmaceutical Company (Pvt) Ltd. Mirpur, Azad Kashmir), Transcam, (Chas A. Mendoza Karachi, Pakistan), Traumax (Siza International (Pvt) Ltd. Lahore, Pakistan), Traxyl (Organon Pakistan (Pvt) Ltd. Karachi, Pakistan), Xamig (Highnoon Laboratories, (Pvt) Ltd. Lahore, Pakistan), Xed (Indus Pharma (Pvt) Ltd. Karachi, Pakistan), and Zatranex (Zafa Pharmaceutical Laboratories (Pvt) Ltd. Karachi, Pakistan) was diluted up to 100 mL with double distilled water. The solution 0.1 mL was again diluted up to 25 mL with double distilled water. The aqueous dilution (1 mL) was transferred to volumetric flask (10 mL) and the procedure was repeated as described in “Analytical procedure”. Analysis of TA from tooth pastes For the analysis of TA contents from two tooth pastes the sample (10 g) from each of the TA tooth paste, HI-SALZ (Platinum Pharmaceutical (Pvt) Ltd. Karachi, Pakistan), and Xamic (Spirax International (Pvt) Ltd. Karachi, Pakistan), was dissolved in 100 mL double distilled water. The solution was filtered using Whatmann No. 01 filter paper and 5 mL was again diluted up to 25 mL with double distilled water. The aqueous dilution (1 mL) was transferred to volumetric flask (10 mL) and the procedure was repeated as described in “Analytical procedure”. Recovery (%) of TA from samples by standard addition Each pharmaceutical preparation was prepared as above mentioned procedures for the analysis of TA from dosage forms. Two portions from each consisting of 1 mL were taken in two different volumetric flasks (10 mL). A solution from each proceeded as described in “Analytical procedure” and other was added 5 μg of TA. The solution again proceeded as “Analytical procedure”.

Results and discussion Tranexamic acid (TA) (4-aminomethyl cyclohexanecarboxylic acid) reacts with vanillin (VAN) to form an azomethine derivative 4-{[(4-hydroxy-3-methoxybenzylidene)-amino]-methyl}-cyclohexanecarboxylic acid (TA-VAN) (Figure 1) which absorbs maximally with bathochromic shift to 354 nm with molar absorptivity of 25 160 L·mol−1·cm−1. VAN was then examined as a derivatizing reagent for the spectrophotometric determination of TA. The effects of pH, amount of

F.M.A. Rind, et al: Spectrophotometric determination of tranexamic acid using vanillin

·

177 ·

VAN added, heating time and temperature on the formation of (TA-VAN) derivative were studied.

Figure 2 Effect of volume of 1% reagent on the absorbance of TA derivative

Figure 1 Formation of TA derivative using vanillin as derivatizing reagent

1 Optimization of parameters 1.1 Analytical wavelength For the quantitative analysis, the wavelength of maximum absorbance plays an important role. It is necessary to check that derivatizing reagent should not absorb close to the region where the analyte derivative absorbs. This may cause error in absorption of the drug because the derivatizing reagent is added in excess to complete the reaction quantitatively. To avoid this problem, it is necessary to select the wavelength where the derivatizing reagent indicates minimum absorbance and the analyte derivative shows maximum absorbance value. The absorbance value of 1 µg·mL−1 of TA as VAN derivative was recorded at different wavelengths between 250−500 nm after heating for 15 min at 90 ℃ using buffer pH 1. The maximum absorbance occurred at 354 nm against reagent blank and was selected as optimum. 1.2 Effect of reagent volume The effects of adding various volumes of VAN solution on absorbance of 2 µg·mL−1 TA are given in Figure 2. The volumes of reagent 1% aqueous VAN were varied between 1−4 mL with an interval of 1 mL and the absorbance was measured at λmax 354 nm. The similar absorbance was observed with addition of 2−3 mL therefore the addition of 3 mL 1% (w/v) VAN aqueous solution was selected. 1.3 Effect of order of mixing the reagents The order of adding reagents during derivatization process has important role in accuracy of results and enhancement of absorbance. In the present study, it was observed that the addition of buffer pH 1 (1 mL) to TA solution (1 mL) followed by the 3 mL VAN reagent 1% (w/v) resulted in a decrease in absorbance value. Taking

the reagent first and then adding the buffer, followed by TA solution also decreased the absorbance value. The maximum absorbance value was observed when 3 mL of reagent VAN was added to the standard solution of TA followed by buffer (1 mL) pH 1. The contents were then heated on water bath and the volume was adjusted to 10 mL with ethanol. 1.4 Optimization of heating time and temperature for the formation of derivative To achieve the maximum absorbance value for an analyte by the formation of stable derivative, the selection of optimum time and temperature is essential. The effect of time on the formation of derivative in terms of absorbance of 1 µg·mL−1 TA solution in the presence of 1% VAN solution was checked at 354 nm from 0−30 min with an interval of 5 min. A similar absorbance was observed after heating for 15 min. Therefore, the heating time of 15 min at 90 ℃ was considered as optimal. 1.5 Effects of solvents The effects of various solvents such as toluene, cyclohexane, acetone, carbon tetrachloride, acetonitrile, methanol, 1-propanol, isopropanol, 1-butanol, amyl alcohol, isoamyl alcohol, 1,4-diaxone, ethyl acetate and nitrobenzene on the absorbance of 1 µg·mL−1 TA using VAN as a derivatizing agent were examined. From each of the solvents 1 and 2 mL was added after the addition of 1% aqueous solution of VAN, and 1 mL HCl-KCl buffer (pH 1) followed by heating for 15 min at 90 ℃. Ethanol proved to be the best choice. 1.6 Effect of pH The effect of adding 1 mL of 1 mol·L−1 buffers of pH range 1-10 on the absorbance of 2 µg·mL−1 TA solution was studied at optimized conditions. It is evident from Figure 3 that the maximum absorbance was observed at buffer pH 1 and addition of buffers pH 2 to pH 8 decreased the absorbance. Addition of buffer of pH 9 and above produced precipitation. Therefore, the HCl-KCl buffer of pH 1 was selected as optimal.

·

178 ·

药学学报 Acta Pharmaceutica Sinica 2009, 44 (2): 175−180 Table 1 Analysis of TA from capsules (Amount labeled 250 mg/capsule) Amount found Relative Recovery mg/capsule RSD/% deviation from /% labeled value/% (Standard deviation)

Name of preparation

Figure 3

Effect of pH on derivatization of TA

2

Interference study The effect of possible presence of associated materials such as sodium chloride, mannitol, sorbitol, lactose, sucrose, glucose, galactose and fructose was investigated at 10 times the concentration of TA and it was observed that none of these substances interfered with change in absorbance of within ± 4%. 3 Stability of the derivative The stability of TA-VAN derivative was examined but no change in absorbance more than 5% was observed within 48 h. 4 Calibration plot The effect of variation in the concentration of TA on its absorbance was studied. A linear calibration curve was obtained which obeyed the Beer’s law within

Aneptil

249.0 (1.0)

0.40

0.40

96.0

Btrol

249.9 (1.0)

0.40

0.04

97.8

Haematrix

250.3 (0.6)

0.23

0.12

99.0

Maxna

249.0 (2.6)

0.86

0.40

99.6

Ranmic

250.1 (2.2)

1.06

0.06

98.4

Transamin

249.3 (2.1)

0.83

0.26

100

Transcam

250.1 (1.0)

0.41

0.04

96.8

Tranxic

249.5 (2.7)

1.06

0.84

98.0

Traumax

250.3 (3.3)

1.30

0.12

96.5

Traxyl

249.9 (2.2)

0.86

0.02

99.9

Xamig

251.0 (1.0)

0.40

0.40

98.3

Xed

250.6 (2.1)

0.85

0.25

99.6

Zatranex

250.9 (1.0)

0.42

0.38

95.8

Table 2 Analysis of TA from injections(Amount labeled 250 mg/ injection) Amount found Relative Recovery mg/injection RSD/% deviation from /% labeled value/% (Standard deviation)

Name of preparation B-STOP

250.5 (0.5)

0.96

0.20

99.0

Haematrix

250.4 (0.6)

0.25

0.16

98.8

Maxna

250.6 (1.1)

0.43

0.27

95.5

Tranamin

250.2 (0.4)

0.17

0.08

95.6

Transcam

250.1 (0.5)

0.22

0.04

96.0

Traumax

249.3 (2.1)

0.83

0.26

100

the concentration range 0.5−2.5 µg·mL of TA with coefficient of determination r2 0.999 7 (Figure 4). The sandells sensitivity (0.004) was observed at 0.05

Traxyl

250.4 (0.6)

0.23

0.18

96.8

Xamig

250.3 (1.5)

0.61

0.12

97.0

Xed

250.3 (2.1)

0.85

0.14

99.5

μg·mL−1 TA. The validity of the calibration curve was obtained by the analysis of test solutions of TA (n = 4)

Zatranex

250.7 (0.6)

0.25

0.28

99.9

−1

Table 3

and the percent relative error was found ± 1%−2%. The recovery calculated by standard addition was within the range 96%−99% with RSD 0.2%−5.0%. The pharmaceutical preparations containing TA available in the local market were analyzed to determine the amount of TA quantitatively (Table 1−3).

Analysis of TA from tooth pastes

S. No. Name of preparation

HI-SALZ

02 Xamic

Amount labeled /% (w/w)

0.05

0.05

Amount found /% (Standard deviation)

0.049 (1.15)

0.048 (2.51)

RSD/% Relative deviation from labeled value (± %) Recovery/%

Figure 4 Calibration curve of tranexamic acid 0.001% using vanillin as a derivatizing reagent

01

2.35

5

2

4

95.6

95.0

The mean values at 95% confidence limit of TA capsules from thirteen pharmaceutical brands, injections of ten pharmaceutical brands and tooth pastes of two pharmaceutical brands were (250 ± 0.207 4) mg/capsule, (250.4 ± 0.018 41) mg/injection and (0.048 5 ± 0.000 74)% per tooth paste, respectively (Table 4).

·

F.M.A. Rind, et al: Spectrophotometric determination of tranexamic acid using vanillin Table 4

Optical characteristics, precision and accuracy Parameter

[2]

Value

Beer’s law limits/µg·mL−1

0.5−2.5

Molar absorptivity/L·mol−1 ·cm−1 Sandells sensitivity (0.004 absorbance unit) /µg·mL−1 Regression equation (y)a Slope (b) Intercept (a) Coefficient of determination

25 157 0.05

J

Otorhinolaryngol Relat Spec, 1995, 57: 207−209. [3]

Fiechtner BK, Nuttall GA, Johnson ME, et al.

Plasma

tranexamic acid concentrations during cardiopulmonary bypass [J]. [4]

0.999 7

Anaesth Analg, 2001, 92: 1131−1136.

Jansen A, Andreica S, Claeys M, et al.

Use of tranexamic

acid for an effective blood conservation strategy after total

0.17−5

Relative deviation (± %) Mean value mg/capsule ± range of error at (95% confidence limit) of thirteen capsules of various pharmaceutical companies Mean value mg/ampoule ± range of error at (95% confidence limit) of ten ampoules of various pharmaceutical companies Mean value % tooth paste ± range of error at (95% confidence limit) of two tooth pastes of two pharmaceutical companies

Effect of local

tranexamic acid gel in the treatment of epistaxis [J].

0.159 3 0

Relative standard deviation (± %)

Tibbelin A, Aust R, Bende M, et al.

179 ·

knee arthroplasty [J].

0.04−4 250 ± 0.207 4

[5]

250.4 ± 0.018 41

[6]

Br J Anaesth, 1999, 83: 596− 601.

Martindale XXXI [M].

London: Royal Pharmaceutical

Society of Great Britain, 1996: 771−772. Maeda K, Naganuma M.

Topical trans-4-aminomethylcy-

clohexane carboxylic acid prevents ultraviolet radiationinduced pigmentation [J].

0.048 5 ± 0.000 7

J Photochem Photobiol B, 1998,

47: 136−141. [7]

Day to day reproducibility / repeatability For the determination of intra- and inter-day reproducibility of the method, the aqueous standard solution (1 mL) of 10 μg·mL−1 TA was taken in three different calibrated volumetric flasks (10 mL) and the procedure was followed as described in “Analytical procedure”. The absorbance was measured against reagent blank at 354 nm. The above procedure was repeated for three days (n = 3). The mean absorbances of intra- and inter-day reproducibilities were observed as 0.16 and 0.161 with (RSD) values 0.003 6% and 0.095% respectively.

Dalmau A, Sabaté A, Koo M, et al.

Prophylactic use of

tranexamic acid and incidence of arterial thrombosis in liver

5

transplantation [J]. [8]

Anesth Analg, 2001, 93: 516.

Ansari TM, Raza A, Atta-Ur-Rehman.

Spectrophotometric

determination of tranexamic acid in pharmaceutical bulk and dosage forms [J]. [9]

Anal Sci, 2005, 21: 1133−1135.

El-Aroud KA, Abushoffa AM, Abdellatef HE.

Spectropho-

tometric and spectrofluorimetric methods for the determination of tranexamic acid in pharmaceutical formulation [J].

Chem

Pharm Bull, 2007, 55: 364−367. [10] Atmaca S.

Spectrophotometric determination of tranexamic

acid with 2, 4, 6-trinitrobenzosulfonic acid [J].

Acta Pharm

Turcica, 1989, 31: 115−118. [11] Duangrat C, Wongsri K, Pongpaibul Y. Spectrofluorimetric determination of tranexamic acid in hydrogel patch formula-

Conclusion

tions by derivatization with naphthalene-2, 3-dicarboxaldehyde/

The developed method is simple, accurate, precise, inexpensive and less time consuming. The molar absorptivity of the developed method is much more than un-derivatized UV method and the λmax is considerably higher than this method. This is an important quality of the developed method which is used to avoid the interferences from associated materials which may absorb in the UV region. The method was applied for the determination of TA contents from various pharmaceutical preparations.

cyanide [J].

Tranexamic acid

as a mouthwash in anticoagulant-treated patients undergoing An alternative method to discontinuing

anticoagulant therapy [J]. 1993, 75: 29−31.

dosage forms [J].

Anal Lett, 2006, 39: 2217−2226.

[13] Mishra P, Garg G.

Spectrophotometric determination of

tranexamic acid in pharmaceutical dosage forms [J].

Ind J

Pharm Sci, 2005, 67, 489−491. [14] Chitra K, Sujatha K, Ahmed IR, et al.

Spectrophotometric

estimation of tranexamic acid in bulk and Pharmaceutical dosage form [J].

Ind J Pharm Sci, 2004, 66: 836−839.

[15] Mohamed SR, Toubar SS, Sultan MA, et al.

Ultraviolet spec-

drugs via their charge-transfer complexes with tetracyano-

Borea G, Montebugnoli L, Capuzzi P, et al.

oral surgery.

Utility of certain π-acceptors for the spectropho-

tometric determination of tranexamic acid in commercial

trophotometric determination of primary amine-containing

References [1]

[12] Raza A.

J Cosmet Sci, 2007, 58: 215−227.

Oral Surg Oral Med Oral Pathol,

ethylene [J].

Microchim Acta, 2003, 143: 281−285.

[16] Lacroix C, Levert P, Laine G, et al.

Microanalysis of two

antifibrinolytics (epsilon-aminocaproic acid and tranexamic acid) by liquid chromatography and fluorometry [J]. Chromatogr, 1984, 309: 183−186.

J

·

药学学报 Acta Pharmaceutica Sinica 2009, 44 (2): 175−180

180 ·

[17] Hosiana BT, Endang S, Mochammad Y, et al.

Densitometric

[23] Abrahamsson M.

Determination of a prodrug of tranexamic

determination of tranexamic acid in tablets: validation of the

acid I whole body by reversed phase liquid chromatography

method [J].

after pre-column derivatization with fluorescamine [J].

J Liq Chromatogr Relat Technol, 2005, 28:

J

Pharm Biomed Anal, 1986, 4: 399−406.

3243−3254. [18] Elworthy PM, Tsementzis SA, Westhead D, et al.

Determina-

[24] Matsubayashi K, Kojima C, Tachizawa H.

Determination of

tion of plasma tranexamic acid using cation-exchange high-

tranexamic acid in human serum by high-performance liquid

performance liquid chromatography with fluorescence detec-

chromatography using selective pre-column derivatization with

tion [J].

phenyl isothiocyanate [J].

J Chromatogr, 1985, 343: 109−117.

[19] Hadad GM, El-Gindy A, Waleed MM.

Optimization and

validation of an HPLC-UV method for determination of

J Chromatogr, 1988, 433: 225−

234. [25] Huertas-Pérez JF, Heger M, Dekker H, et al.

Simple, rapid,

tranexamic acid in a dosage form and in human urine [J].

and sensitive liquid chromatography-fluorescence method for

Chromatographia, 2007, 66: 311−317.

the quantification of tranexamic acid in blood [J].

[20] Khuhawar MY, Rind FMA.

HPLC determination of tranex-

amic acid in pharmaceutical preparations and blood [J].

J Chroma-

togr A, 2007, 1157: 142−150. [26] Sato K, Tobita Y, Iwabuchi K, et al.

Determination of tranex-

amic acid and vitamins by high performance liquid chroma-

Chromatographia, 2001, 53: 709.

tography with peroxyoxalate chemiluminescence detection [J]. [21] Elworthy PM, Tsementzis SA, Westhead D, et al.

Determina-

tion of plasma tranexamic acid using cation-exchange

Anal Sci, 1997, 13: 471−474. [27] Keucher TR, Solow EB, Metaxas J, et al.

Gas-chroma-

high-performance liquid chromatography with fluorescence

tographic determination of an antifibrinolytic drug, ε-amino-

detection [J].

caproic acid [J].

J Chromatogr, 1985, 343: 109−117.

[22] Chang Q, Ophelia QPY, Chow MSS.

Liquid chromatography-

Clin Chem, 1976, 22: 806−810.

[28] Vessman J, Stromberg S.

Determination of tranexamic acid

tandem mass spectrometry method for the determination of

in biological material by electron capture gas chromatography

tranexamic acid in human plasma [J].

after direct derivatization in an aqueous medium [J].

805: 275−280.

J Chromatogr B, 2004,

Chem, 1977, 49: 369−373.

Anal